Literature DB >> 12019078

Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Sofia Perea1, José L López-Ribot, Brian L Wickes, William R Kirkpatrick, Olga P Dib, Stefano P Bachmann, Suzanne M Keller, Marcos Martinez, Thomas F Patterson.   

Abstract

Candida dubliniensis is a newly identified species of Candida that is phenotypically similar to but genetically distinct from C. albicans. This organism has been recovered with increasing frequency from the oral cavities of human immunodeficiency virus (HIV)-infected and AIDS patients and has been implicated as a causative agent of oral candidiasis and systemic disease. In the present study we characterized the molecular mechanisms of resistance to fluconazole (FLC) in C. dubliniensis clinical isolates from two different HIV-infected patients with oropharyngeal candidiasis. Isolates were identified to the species level by phenotypic and genotypic tests. DNA-typing techniques were used to assess strain identity. Antifungal susceptibility testing was performed by NCCLS techniques. Northern blotting analysis was used to monitor the expression of genes encoding lanosterol demethylase (ERG11) and efflux transporters (CDR and MDR1) in matched sets of C. dubliniensis-susceptible and -resistant isolates by using probes generated from their homologous C. albicans sequences. In addition, ERG11 genes were amplified by PCR, and their nucleotide sequences were determined in order to detect point mutations with a possible effect in the affinity for azoles. Decreasing susceptibilities to FLC were detected in C. dubliniensis isolates recovered from both patients during the course of treatment. FLC-resistant C. dubliniensis isolates from one patient demonstrated combined upregulation of the MDR1, CDR1, and ERG11 genes. Among the isolates from the second patient, all isolates showing decreased susceptibility to FLC demonstrated upregulation of MDR1, whereas the levels of mRNA for the ERG11 genes remained constant and the expression of CDR genes was negligible. Fourteen point mutations were found in the ERG11 genes of the isolates with decreased susceptibility to FLC. These data demonstrate that the development of azole resistance in C. dublinensis clinical isolates from HIV-infected patients treated with FLC is mediated by multiple molecular mechanisms of resistance, similar to the observations found in the case of C. albicans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019078      PMCID: PMC127221          DOI: 10.1128/AAC.46.6.1695-1703.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  46 in total

1.  Development of simultaneous resistance to fluconazole in Candida albicans and Candida dubliniensis in a patient with AIDS.

Authors:  M Ruhnke; A Schmidt-Westhausen; J Morschhäuser
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

2.  Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy.

Authors:  H Valdez; B M Gripshover; R A Salata; M M Lederman
Journal:  AIDS       Date:  1998-03-26       Impact factor: 4.177

3.  Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans.

Authors:  Patrick Marichal; Luc Koymans; Staf Willemsens; Danny Bellens; Peter Verhasselt; Walter Luyten; Marcel Borgers; Frans C S Ramaekers; Frank C Odds; Hugo Vanden Bossche
Journal:  Microbiology       Date:  1999-10       Impact factor: 2.777

4.  Oral Candida dubliniensis as a clinically important species in HIV-seropositive patients in the United States.

Authors:  T F Meiller; M A Jabra-Rizk; A a Baqui; J I Kelley; V I Meeks; W G Merz; W A Falkler
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1999-11

5.  Prevalence of Candida dubliniensis isolates in a yeast stock collection.

Authors:  F C Odds; L Van Nuffel; G Dams
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  Isolation of C. dubliniensis from insulin-using diabetes mellitus patients.

Authors:  A M Willis; W A Coulter; D J Sullivan; D C Coleman; J R Hayes; P M Bell; P J Lamey
Journal:  J Oral Pathol Med       Date:  2000-02       Impact factor: 4.253

7.  Identification of Candida dubliniensis in a study of HIV-seropositive pediatric dental patients.

Authors:  D M Brown; M A Jabra-Rizk; W A Falkler; A A Baqui; T F Meiller
Journal:  Pediatr Dent       Date:  2000 May-Jun       Impact factor: 1.874

8.  Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea.

Authors:  M J McCullough; K V Clemons; D A Stevens
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

Review 9.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  Modeling cytochrome P450 14 alpha demethylase (Candida albicans) from P450cam.

Authors:  P E Boscott; G H Grant
Journal:  J Mol Graph       Date:  1994-09
View more
  33 in total

1.  Molecular characterization of fluconazole resistance in a case of Candida albicans ocular infection.

Authors:  Preeti Pancholi; Steven Park; David Perlin; Christine Kubin; Phyllis Della-Latta
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

2.  Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.

Authors:  Sabrina Schubert; P David Rogers; Joachim Morschhäuser
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

3.  TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2.

Authors:  Alix T Coste; Mahir Karababa; Françoise Ischer; Jacques Bille; Dominique Sanglard
Journal:  Eukaryot Cell       Date:  2004-12

4.  Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CdCDR1 and CdCDR2 expression.

Authors:  Emmanuelle Pinjon; Colin J Jackson; Steven L Kelly; Dominique Sanglard; Gary Moran; David C Coleman; Derek J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.

Authors:  Donna M MacCallum; Alix Coste; Françoise Ischer; Mette D Jacobsen; Frank C Odds; Dominique Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

6.  Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor.

Authors:  John-Paul Vermitsky; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation.

Authors:  Spencer W Redding; William R Kirkpatrick; Stephen Saville; Brent J Coco; William White; Annette Fothergill; Michael Rinaldi; Tony Eng; Thomas F Patterson; Jose Lopez-Ribot
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

8.  Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.

Authors:  Marcos Martinez; José L López-Ribot; William R Kirkpatrick; Brent J Coco; Stefano P Bachmann; Thomas F Patterson
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

9.  Mechanisms of azole resistance in petite mutants of Candida glabrata.

Authors:  Sophie Brun; Thierry Bergès; Pascal Poupard; Carole Vauzelle-Moreau; Gilles Renier; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected Galleria mellonella Larvae.

Authors:  Ana Carolina R Souza; Beth Burgwyn Fuchs; Henrique M S Pinhati; Ricardo A Siqueira; Ferry Hagen; Jacques F Meis; Eleftherios Mylonakis; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.